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LIVER

Outcomes of Exercise Interventions in Patients With
Advanced Liver Disease: A Systematic Review of
Randomized Clinical Trials
Taher Jamali, MD*1, Taaj Raasikh, MD*1, Gabriel Bustamante, MD1, Amy Sisson, MS2, Puneeta Tandon, MD3, Andres Duarte-Rojo, MD4 and
Ruben Hernaez, MD5,6,7
INTRODUCTION: Frailty and sarcopenia are common complications of advanced liver disease. Owing to associated

morbidity/mortality, there have been targeted efforts to prevent and/or improve both by enrolling these
patients in focused exercise programs. This review systematically analyzes the data of randomized
clinical trials (RCTs) on anthropometric, physical fitness, quality-of-life, and safety outcomes of
exercise interventions in patients with advanced liver disease.
METHODS:

Two authors independently searched trials on PubMed and EMBASE from inception up to November
18, 2021. A third independent arbitrator adjudicated all disagreements. We qualitatively summarized
these outcomes as follows: (i) muscular fitness (maximal inspiratory/expiratory pressures, muscle size,
muscle strength, and bioimpedance testing), (ii) cardiorespiratory fitness (cardiopulmonary exercise
testing and 6-minute walk distance), (iii) quality of life, and (iv) others (safety or frailty indices).

RESULTS:

There were 11 RCTs (4 home-based interventions) with 358 participants. Interventions ranged from 8
to 14 weeks and included cycling, walking, resistance exercises, balance and coordination training, and
respiratory exercises. All described outcomes compared preintervention with postintervention
measurements. Nine studies showed statistically significant improvements in at least 1 physical fitness
variable. Ten studies showed statistically significant improvements in at least 1 muscular fitness
variable. Six studies showed statistically significant improvements in at least 1 quality-of-life variable.
Attrition rates ranged from 5% to 36%, and adherence rates ranged very widely from 14% to 100%.
Only 1 study reported frailty indices. Notably, no complications of portal hypertension were seen in
intervention groups in the 9 studies that reported these data.

DISCUSSION:

A review of 11 RCTs with 358 participants with advanced liver disease demonstrates that exercise
interventions can have favorable outcomes on muscular/cardiorespiratory fitness and quality of life.
Although attrition and adherence varied, these interventions seem to be safe in patients with cirrhosis
and are well tolerated.

SUPPLEMENTARY MATERIAL accompanies this paper at http://links.lww.com/AJG/C565
Am J Gastroenterol 2022;117:1614–1620. https://doi.org/10.14309/ajg.0000000000001883

INTRODUCTION
Frailty and sarcopenia are prevalent complications in patients
with advanced liver disease and cirrhosis. Sarcopenia is deﬁned as
a loss of skeletal muscle mass or function (muscular ﬁtness), and
in advanced liver disease, it is multifactorial in etiology with a

signiﬁcant impact on morbidity and mortality. Numerous studies
suggest that sarcopenia is found in anywhere from 30% to 70% of
patients with cirrhosis (1–4). Patients with cirrhosis who also
have sarcopenia are at higher risk of mortality from sepsis than
cirrhotic patients without sarcopenia (4).
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Treatment of sarcopenia and frailty in advanced liver disease
has focused on a combination of positive lifestyle changes
(i.e., increasing daily physical activity) and adequate nutrition.
Maintaining adequate protein intake and supplementation with
branched-chain amino acids and leucine has been shown to improve levels of serum albumin and potentially protect against
malnutrition and protein breakdown (5,6). It is also critical to
recognize and optimize nutrition in the subset of patients who
have sarcopenic obesity because this phenotype can be associated
with increased mortality (7,8).
Several studies have been published about the beneﬁts of exercise interventions in patients with early stages of liver disease.
However, although exercise is recommended as an intervention
in recent guidelines, we lack a systematic analysis of exercise
tolerance and beneﬁt in patients with advanced ﬁbrosis and cirrhosis. Accordingly, our study provides a comprehensive systematic review regarding the safety and eﬃcacy of exercise
interventions in patients with advanced liver disease.

METHODS
Data sources and searches

We selected eligible studies by searching the PubMed and
EMBASE electronic databases using predetermined search engines (see Table 1, Supplementary Digital Content 1, http://links.
lww.com/AJG/C565) from inception to November 18, 2021. Our
primary goal was to assess muscular and cardiorespiratory ﬁtness
(CRF) or other metrics of physical performance, quality-of-life,
and safety outcomes of exercise interventions in patients with
advanced liver disease. Per the American College of Sports
Medicine Health-Related Physical Fitness Manual, physical ﬁtness comprises 5 components: body composition (or anthropometrics), muscular strength and endurance (both equal muscle
ﬁtness), ﬂexibility, and cardiorespiratory ﬁtness (CRF) (9).
Study selection

We conducted a systematic review following the Preferred
Reporting Items for Systematic reviews and Meta-Analyses
(PRISMA) statement (10). Two independent reviewers (T.J. and
T.R.) selected studies that addressed anthropometric, muscle
mass/strength, CRF, frailty, quality-of-life, and safety outcomes
in patients with advanced liver disease (either histologically deﬁned as ﬁbrosis stage F3 or F4 with or without portal hypertension or clinically deﬁned as cirrhosis based on laboratory and
imaging evidence) following the inclusion and exclusion criteria
(see Table 2, Supplementary Digital Content 1, http://links.lww.
com/AJG/C565). A third reviewer resolved disagreements (R.H.).
Study outcomes, data extraction, synthesis, and
quality assessment

For each study, we assessed baseline study participant characteristics as follows: number of participants in each study group,
percentage of participants in each Child-Turcotte-Pugh (CTP)
class, types and schedule of exercise interventions, attrition rate,
adherence rate, and information on any other intervention supplementing exercise if applicable (i.e., nutrition and diet counseling). We deﬁned attrition as the percentage of participants in
the study group that did not complete the study. We described
adherence as the percentage of participants in the study group
that participated in the exercise intervention as recommended by
each study’s initial design. We particularly searched for studies
that included exercise interventions that had been shown to aﬀect
© 2022 by The American College of Gastroenterology

physical ﬁtness, reverse sarcopenia, and reverse frailty, which
included aerobic training (i.e., cycling, jogging, and respiratory
exercises), resistance training (i.e., resistance bands and weight
lifting), and balance and strength training (i.e., sitting to standing
exercises and leg raises). We excluded studies that did not include
1 of these types of interventions. We also excluded studies that did
not prioritize the outcomes described below.
We qualitatively summarized the following outcomes: (i)
muscular ﬁtness (muscle size, muscle strength, respiratory
muscle strength (maximal inspiratory pressure and maximal
expiratory pressure), muscle/lean body/body cell mass, isometric grip strength, and bioimpedance testing), (ii) CRF (6minute walk distance [6MWD], peak oxygen consumption
[peakVO2], ventilatory anaerobic threshold time, ventilatory
eﬃciency, forced expiratory ﬂow 25%–75%, root mean square
[RMS] of the diaphragm and functional capacity, and 2-minute
step test), (iii) self-reported quality-of-life outcomes (Chronic
Liver Disease Questionnaire [CLDQ] parameters, Short-Form
36-Item Survey [SF-36] parameters, Sickness Impact Proﬁle
parameters, and EuroQol visual analog scale [EQ-VAS] parameters), and (iv) others (safety or frailty indices including
complications of cirrhosis from exercise interventions). The
preintervention measurements were compared with the postintervention measurements for all outcomes described.
We provided qualitative data as reported in the studies for the
baseline characteristics of the study participants as described
above. We primarily focused on statistically signiﬁcant changes in
the intervention group compared with their reported baseline for
outcome data. We deﬁned statistical signiﬁcance by a P-value of
less than 0.05 and a 95% conﬁdence interval. We also reported
data on statistically signiﬁcant diﬀerences between the intervention and control groups (if any). We decided not to pursue
a meta-analysis because of the substantial heterogeneity of the
studies in outcome data and baseline study characteristics. We
instead provided a qualitative summary of the data collected.
Ranges were reported from the lowest value to the highest value.
Mean values were reported as an average of the values with a
standard deviation.
We independently assessed the methodological quality of the
articles using a modiﬁed revision of version 2 of the Cochrane riskof-bias tool for randomized trials (RoB 2), resulting in each study
being classiﬁed in 1 of the following categories: high risk of bias, low
risk of bias, or some concerns for bias (11). We analyzed 5 domains,
including the risk of bias arising from the randomization process,
risk of bias due to deviations from the intended intervention (eﬀect
of intervention assignment), risk of bias due to deviations from the
intended intervention (eﬀect of adherence to intervention), risk of
bias due to missing outcome data, and risk of bias in the measurement of outcomes. The speciﬁc parameters that were
addressed in each domain for each study are presented in Table 1.

RESULTS
Our search algorithm identiﬁed 11 randomized clinical trials
(RCTs) with a total of 358 participants (see Figure 1, Supplementary Digital Content 1, http://links.lww.com/AJG/C565). All
the studies were published from the years 2014–2020. Six trials
included on-site exercise interventions (12–17), 4 trials solely
included home-based exercise interventions (18–21), and 1 trial
had partially home-based exercise interventions (22). Prescribed
exercises ranged from 8 to 14 weeks and included cycling,
The American Journal of GASTROENTEROLOGY
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Table 1. Risk of bias among studiesa
First Author, year

Domain 1

Domain 2

Domain 3

Domain 4

Domain 5

Overall risk of bias

Limongi, 2014

Low

Low

Moderate

Low

Moderate

Moderate

Román, 2014

Low

Low

Low

Low

Low

Low

Zenith, 2014

Low

Low

Moderate

Low

Moderate

Moderate

Limongi, 2016

Low

Moderate

Moderate

Low

Low

Moderate

Macias-Rodriguez, 2016

Low

Moderate

Low

Low

Low

Low

Román, 2016

Low

Low

Moderate

Low

Low

Low

Kruger, 2018

Low

Low

Moderate

Low

Low

Low

Wallen, 2019

Low

Low

Moderate

Low

Low

Low

Aamann, 2020

Low

Low

Moderate

Low

Low

Low

Chen, 2020

Low

High

Moderate

Low

Moderate

High

Lai, 2020

Moderate

Low

Moderate

Low

Low

Moderate

Domain 1: Risk of bias arising from the randomization process.
Domain 2: Risk of bias due to deviations from the intended intervention (effect of assignment to intervention).
Domain 3: Risk of bias due to deviations from the intended intervention (effect of adhering to intervention).
Domain 4: Risk of bias due to missing outcome data.
Domain 5: Risk of bias in measurement of outcomes.
a
Analyzed using a modified version of the RoB2 tool (a revised Cochrane risk-of-bias tool for randomized trials).

walking, resistance exercises, balance and coordination training,
and respiratory exercises.
Baseline characteristics of the participants

There were a total of 358 participants: 192 participants in the
exercise groups and 166 participants in the control groups. The
sample size for exercise groups ranged from 5 to 58 participants
compared with 10–25 participants in the control group. The total
sample size of the studies (including both exercise and control
groups) ranged from 17 to 83 participants.
Nine studies reported CTP cirrhosis class data (12–14,16,17,22)
and 2 did not (15,21). The CTP class for the studies varied significantly, with 1 study by Román et al. (12) reporting 100% of the
participants with CTP class A cirrhosis. Another study by Chen
et al. (20) reported 100% of the participants in classes B/C. The
mean percentages of participants with reported CTP classes were
65% (SD 19) for class A and 37% (SD 21) for CTP classes B/C.
Type and schedule of exercise intervention and
other interventions

The type of rehabilitation varied across the 11 studies and included
aerobic exercises, resistance exercises, balance and coordination
training, scheduled counseling/motivation, and personal activity
trackers. The weekly schedules for each study varied from daily to a
minimum of 3 times per week. The study duration ranged from 8
weeks to 12 weeks.
Eight studies included some form of aerobic exercise (6
studies with cycling [12,13,16–18,22], 2 studies with walking
(12,17), and 2 studies with respiratory exercises (15,21)). Six
studies included resistance and strength exercises, such as resistance bands or weight lifting (12,14,16,19,21,22). Three
studies included some form of scheduled exercise counseling
and/or motivation (19,20,22). Two studies included balance and
coordination training in the exercise regimen (12,16). Finally, 2
The American Journal of GASTROENTEROLOGY

studies included a personal activity tracker so that participants
and study coordinators could follow activity levels (20,22).
Six studies supplemented dietary counseling and society
guideline-based nutritional therapy in addition to physical rehabilitation (13–16,18,20). One study speciﬁcally added leucine
supplementation (17).
Attrition and adherence rates

Adherence was measured by participation in the assigned exercises in each of the studies (in either supervised or unsupervised
settings). Achieving speciﬁc intensities or duration of exercise was
not necessarily delineated. One study did not include information
about the adherence rate (15). Two studies did not include information about attrition and adherence rates (13,21). Of the
remaining 8 studies that did include these data about intervention
groups, attrition rates ranged from 5% to 36% and adherence
rates ranged very widely from 14% to 100%. The mean attrition
rate was 16% (SD 11), and the mean adherence rate was 77%
(SD 27).
Outcomes

Muscular ﬁtness. Overall, 10 of the 11 studies showed statistically
signiﬁcant improvements in at least 1 muscular ﬁtness variable
compared with participant baselines (12–18,20–22). Variation
existed among the speciﬁc variables studied; however, many
studies used computed tomography, magnetic resonance imaging, speciﬁc appendage measurements, bioelectrical impedance
analysis, and dual energy X-ray absorptiometry (DEXA) to obtain
anthropomorphic data. Only 1 study did not demonstrate any
statistically signiﬁcant change in any of the muscular ﬁtness
variables analyzed (19). Four studies showed statistically signiﬁcant improvement in thigh circumference (12,13,17,18). Two
studies showed statistically signiﬁcant improvement in maximal
inspiratory pressure (15,21). Other individual studies showed
statistically signiﬁcant improvements in muscle strength/size/dry
VOLUME 117 | OCTOBER 2022 www.amjgastro.com
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lean mass (14), bioimpedance phase angle (16), body mass index
(17), computed tomography-based psoas muscle index (20),
maximal expiratory pressure (21), and isometric grip strength
(22) (Table 2).

RMS of the diaphragm (15), VE/VCO2 (16), and steps climbed
during the 2-minute step test (17)). One study showed a statistically signiﬁcant improvement in quality-of-life variables (subscores of the CLDQ (13)). (Table 2)

Cardiorespiratory fitness

Frailty, complications of cirrhosis, and safety

Nine of the 11 studies showed statistically signiﬁcant improvements in at least 1 CRF variable compared with participant
baselines. Variables across studies were collected using cardiopulmonary exercise testing protocols, cycloergonomic testing,
and 6MWD measurements. Two studies did not demonstrate any
statistically signiﬁcant change in any of the physical ﬁtness variables analyzed (19, 22). Five studies showed statistically signiﬁcant improvement in 6MWD (13,14,17,18,20). Three studies
showed statistically signiﬁcant improvements in peakVO2 and VE
(13,16,18). Other individual studies showed statistically signiﬁcant improvements in ventilatory anaerobic threshold time (12),
forced expiratory ﬂow 25%–75% (21), RMS of the diaphragm and
functional capacity (15), and steps climbed in the 2-minute step
test (17) as outlined in Table 2.
Speciﬁc 6MWD increases in meters were noted as follows: 423
6 60 to 482 6 87 (20); 509 6 85 to 541 6 100 (14); 503.6 6 96.3 to
534.0 6 102.7 (18); 529.1 6 131.8 to 570.5 6 112.0 (13); and 365
(160–420) to 445 (250–500) (17). peakVO2 measurements also
increased in the exercise groups in 3 of the studies, measured in
mL/kg/min (23.3 6 7.7 to 27.3 6 6.2 (13); 21.4 6 0.8 to 23.0 6 1.3
(12); and 18.5 6 4.5 to 21.4 6 6.7 (18)). Respectively, in these
studies, 6MWD increased on average by 48.3 m and peakVO2
measurements increased on average by 2.83 mL/kg/min.

Only 2 studies reported frailty indices (12,19). The study by Lai
et al. (19) reviewed liver frailty index data and did show an improvement after interventions in each arm; however, it was not
statistically signiﬁcant. The study by Román et al. (12) reviewed
data on the Timed Up and Go test—an estimate of fall risk—and
they demonstrated a statistically signiﬁcant improvement in the
test after 12 weeks in the intervention group. Notably, no complications of cirrhosis, including decompensation events, were
seen in any of the intervention groups in the 9 studies that
reported these data. Another key ﬁnding in the study by MaciasRodriguez et al. was that patients with elevated hepatic venous
pressure gradient (HVPG) were included and were safely able to
participate in exercise interventions. The study demonstrated a
statistically signiﬁcant improvement in HVPG that favored the
exercise group (16).

Quality of life

Six studies showed statistically signiﬁcant improvements in at
least 1 quality-of-life variable compared with participant baselines (13–17,21). One study did not report any quality-of-life
outcome data (12). Five studies reported data using CLDQ
(13,16,18,19,22), 2 studies using EQ-VAS (13,18), 4 studies using
SF-36 (14,15,17,21), and 1 study using the Sickness Impact Proﬁle
(20). Two studies (13,16) reported a statistically signiﬁcant improvement in 1 CLDQ parameter each (fatigue and worry). Four
studies (14,15,17,21) reported a statistically signiﬁcant improvement in at least 1 SF-36 parameter (vitality, mental health, general
health, and social function), including 1 study that showed a
statistically signiﬁcant improvement in the overall SF-36 score
(21). One study showed a statistically signiﬁcant improvement in
self-perceived health status from the EQ-VAS score (13). The
remaining studies that did not report any statistically signiﬁcant
changes in quality-of-life scores overall or in the individual parameters are presented in Table 2.
Between group differences

We also examined any statistically signiﬁcant diﬀerences in anthropometrics, muscular or CRF, and quality-of-life outcomes
between the control groups and the intervention groups for each
study. Five studies did not report any statistically signiﬁcant
diﬀerence between study groups (12,18,19,21,22). Of the
remaining 6 studies, 4 studies showed a statistically signiﬁcant
improvement in muscular ﬁtness variables (thigh circumference
(13,17), muscle strength by knee extension peak torque (14),
weight/body mass index (17), and computed tomography-based
psoas muscle index [20]). Five studies showed a statistically signiﬁcant improvement in CRF (6MWD (13,17,20), peakVO2 (13),
© 2022 by The American College of Gastroenterology

Quality assessment of studies

For the 11 RCTs, the modiﬁed Cochrane risk-of-bias tool showed
that most of the studies (6 of 11) were at low risk of bias
(12,14,16–18,22). Only 1 study (20) showed high concern for bias.
The remaining 4 studies only showed moderate concerns for bias
(13,15,19,21). The primary domain across all studies that showed
the highest concern for bias was domain 3, which analyzed the
eﬀect of adherence to intervention. There was also some concern
for bias from the eﬀect of deviation from the intended intervention and from the measurement of outcome data (Table 1).

DISCUSSION
Our review of 11 RCTs with 358 participants with advanced liver
disease evaluating the outcomes of physical rehabilitation demonstrates 3 major ﬁndings. First, having these patients participate
in exercise interventions demonstrated statistically signiﬁcant
improvements in muscular and CRF and quality-of-life variables.
An improvement in sarcopenia measured by thigh circumference
was the most common change in muscular ﬁtness category (observed in 4 of 11 studies) (12,13,17,18). Regarding CRF, a statistically signiﬁcant improvement in 6MWD in the exercise study
group was seen in 5 of the 11 studies (13,14,17,18,20) and peakVO2
in 3 of the 11 studies. These 2 CRF variables have individually and
directly been associated with improved survival in patients with
cirrhosis (24,25). Pimentel et al. demonstrated that low 6MWD
was an independent predictor of mortality (P 5 0.01) (23). In
addition, the study by Faustini Pereira et al. (24) showed that
individuals who covered a 6MWD shorter than 410 m had a
survival rate of 55% compared with a rate of 97% for the individuals who walked more than 410 m (P 5 0.0001). This study
also demonstrated that individuals with peakVO2 values less than
17 mL/kg had a survival rate of 55% compared with a rate of 94%
for those with values more than 17 mL/kg (P 5 0.0001). Thus, the
magnitude of improvement in these variables is more clinically
signiﬁcant because of associations with survival. In addition, 6
studies reported improvement in a quality-of-life variable
(13–17,21). The lack of consensus among the studies could be
explained by the varying outcomes analyzed and the diﬀerent
types of exercises performed by each study.
The American Journal of GASTROENTEROLOGY
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First author,
year

No. of participants in exercise
group(n), control group(n)

% Child-TurcottePugh class

Type and schedule of
exercise intervention

Attrition % and adherence
% of the exercise group

Limongi, 2014

5, 12

NR

Per patient preference for 12 wk
a
Respiratory, resistance, and
abdominal exercises

NR

Román, 2014

10, 10

81% A,
13% B, 6% C

Zenith, 2014

9, 10

74% A,
26% B

Limongi, 2016

22, 23

NR

MaciasRodriguez,
2016

14, 15

Román, 2016

Muscular fitness
outcomesb

Cardiorespiratory
fitness outcomesb

Quality-of-life outcomesb

VOLUME 117 | OCTOBER 2022 www.amjgastro.com

Improvement (1–2) Improvement (10)

Improvement overall (SF-36)

Improvement (3, 4) Improvement (11, 12)

Improvement in general
health, vitality, and social
function (SF-36)

NR

Improvement (3)

Improvement (11, 13)

Improvement in fatigue
(CLDQ) and self-perceived
health status (EQ-VAS)

Daily for 12 wk
Respiratory and abdominal
exercises

36.3%, NR

Improvement (1)

Improvement (14)

Improvement in general and
mental health (SF-36)

64% A,
36% B

3 d/wk for 14 wk
Cycling, strength training,
coordination, and balance

21.4%, 97%

Improvement (5)

Improvement (13)

Improvement in worry (CLDQ)

15, 10

100% A

3 d/wk for 12 wk
Cycling, walking, resistance
exercise, coordination, and
balance

6.67%, 93.61%

Kruger, 2018

20, 20

70% A, 30% B

Wallen, 2019

10, 11

38% A,
62% B/C

Aamann, 2020

20, 19

50% A,
50% B

3 d/wk for 12 wk
Strength training

Chen, 2020

9, 11

78% B,
22% C

Biweekly counseling, PAT per
patient preference for 12 wk
a
PAT and counseling

Lai, 2020

58, 25

46% A,
54% B/C

3 d a week for 12 wk
Cycling and walking
3 d/wk for 8 wk
Cycling

3 d/wk for 8 wk
a
Cycling
3 d/wk (2 supervised and 1
unsupervised) for 8 wk
PAT, counseling, resistance
exercises, cycling, and walking

3 d/wk for 12 wk
a
Coaching, resistance exercise,
and motivation

20%, 83.3%

Improvement (3, 6) Improvement (15)

NR

5%, 55%

Improvement (3)

Improvement (11, 13)

No change (EQ-VAS and
CLDQ)

10%, 95% (supervised), and
75% (unsupervised)

Improvement (7)

No change

No change (CLDQ)

5%, 81.9%

Improvement (8)

Improvement (11)

Improvement in vitality and
mental health (SF-36)

11.1%, 100%

Improvement (9)

Improvement (11)

No change (SIP)

No change

No change

No change (CLDQ)

26%, 14%

1. Maximal inspiratory pressure; 2. Maximal expiratory pressure; 3. Thigh circumference; 4. Body mass index; 5. Bioimpedance phase angle; 6. Mid-arm circumference and skinfold thickness; 7. Isometric grip strength; 8. Muscle
strength, size, and lean dry mass; 9. Psoas muscle index based on computed tomography; 10. Forced expiratory flow (25%–75%); 11.6-minute walk distance; 12. Steps climbed in a 2-minute step test; 13. Peak oxygen consumption or
ventilatory efficiency; 14. RMS of the diaphragm and functional capacity; 15. Ventilatory anaerobic threshold time.
CLDQ, Chronic Liver Disease Questionnaire; EQ-VAS, EuroQol visual analog scale; NR, not reported, PAT, physical activity tracker; SF-36, Short-Form 36-Item Survey; SIP, Sickness Impact Profile.
a
Indicates home-based exercises.
b
Statistically significant outcomes compared with preintervention baseline.

Jamali et al.
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Secondly, 9 of the 11 studies reported no complications or
decompensation of a patient’s cirrhosis caused by physical activity, regardless of the CTP class. The other 2 studies did not
comment on complications because this was not a primary outcome in most included studies. Another important ﬁnding from
the study by Macias-Rodriguez et al. (16) was that patients with
elevated HVPG could safely participate in exercise interventions
and actually display improvement in HVPG after weeks of
physical rehabilitation. Furthermore, a nonrandomized uncontrolled pilot study by Berzigotti et al. (25) showed a statistically signiﬁcant improvement in HVPG after an intensive 16week diet and exercise intervention. These ﬁndings suggest that
for patients with advanced liver disease and high CTP scores,
physical rehabilitation is safe and results in favorable improvements in factors that contribute to poor outcomes.
Thirdly, the attrition and adherence rates among participants
varied across studies. Nine of the 11 studies reported complete
data on attrition and adherence rates among participants of the
exercise/intervention groups. The attrition rates ranged from 5%
to 36% for the 9 studies that reported these data. The study by
Ligmoni et al. had the highest attrition rate at 36% because 8
patients were excluded from the initial intervention group of 22
participants. Three patients declined to do the exercises, 3 died
before starting the intervention, and 2 underwent liver transplantation. The study by Lai et al. from 2020 had the second
highest attrition rate of 26%. Otherwise, attrition rates were relatively lower for the other studies. Concerning adherence, studies
with home-based, mostly unsupervised exercises had adherence
rates ranging from 14% to 100% among participants. Those who
had supervision during physical exercises had an adherence rate
between 81% and 100%. Overall, studies that had supervised
physical activity sessions rather than home-based exercises tended to have a higher adherence rate (Table 2). The diﬀerences in
supervised versus unsupervised interventions can also aﬀect efﬁcacy and outcomes of exercise interventions. For example, the
between-group changes in peakVO2 in the intervention group
compared with the control group was lower in the study by
Kruger et al. (18) (a home-based exercise study) compared with
the study by Zenith et al. (13) (a supervised exercise study). As
discussed earlier, lower adherence in unsupervised studies can
negatively aﬀect exercise-related gains. However, these studies
also acknowledge the diﬃculties with implementation of regular
supervised programs, including barriers of transportation, patient costs, and time commitment.
Finally, our review demonstrates a potential for improvement in
sarcopenia and frailty in patients with cirrhosis. Román et al. (12)
showed a statistically signiﬁcant improvement in risk of falls using
the Timed Up and Go test, and another nonrandomized uncontrolled trial by Williams et al. (26) showed a statistically signiﬁcant improvement in functional capacity using the short physical
performance battery test after a 12-week home-based exercise program. The study by Lai et al. did show an improvement in liver frailty
index (LFI); however, this was not statistically signiﬁcant likely because of the relatively small sample size. The other 9 studies in our
review of randomized trials did not evaluate frailty metrics. Thus,
there is clearly a lack of connection between risk estimation (frailty)
and interventions for risk reduction in cirrhosis because it seems that
physical rehabilitation studies rarely test for frailty or its reversal.
The strength of our review is that we only evaluated RCTs,
thereby trying to preserve the quality of the studies analyzed and
attempting to minimize bias. Most studies demonstrated a low risk
© 2022 by The American College of Gastroenterology

of bias, and only 1 study demonstrated a high risk of bias (20). Our
review supports the growing evidence that rehabilitation in patients
with cirrhosis is feasible and safe. An additional strength of our
review is that we analyzed outcomes of veriﬁed quality-of-life
questionnaires. To the best of our knowledge, the impact of rehabilitation on the quality of life of patients with cirrhosis have not
been systematically reviewed previously. There were, however, a
few notable limitations of this review. Because we had very strict
inclusion and exclusion criteria, we were only able to isolate 11
RCTs leading to an overall low sample size of both studies and total
patients. We were also unable to perform a meta-analysis on the
collected data because of the heterogeneity of outcomes and types
of exercise interventions across the studies. Finally, the highly
variable attrition and adherence rates across the studies further
complicate interpretation of the results, with low attrition and
adherence rates in select studies potentially aﬀecting outcomes.
Interestingly, 5 of the 11 studies analyzed did not demonstrate
a statistically signiﬁcant diﬀerence between control and intervention groups in their respective outcomes (12,18,19,21,22).
We hypothesize 3 possible explanations for these absences of
diﬀerences. First, there was a mean 10.53% attrition rate and a
mean 53.92% adherence rate in participants of these 5 trials,
which could have led to underestimation of measurable beneﬁts.
Second, the target population may have diluted the eﬀect. For
example, in the study by Lai et al., the authors commented that the
exercise program was designed for frail and elderly patients and
may not have been rigorous enough for nonelderly nonfrail
subjects. Finally, the exercise interventions likely need to be
combined with a nutritional intervention to show beneﬁt. In 5 of
the 6 studies that demonstrated a diﬀerence in respective outcomes between study groups, it was observed that nutritional
interventions were included (13–17,20). This ﬁnding may suggest
that suﬃcient calorie and protein intake may be necessary
alongside exercise to enhance muscle anabolism and have a
maximal eﬀect on muscle function. Per 2021 AASLD practice
guidelines by Lai et al. (27), the caloric needs of adults with cirrhosis should be personalized with indirect calorimetry, with
limited data supporting a caloric intake of 35 kcal/kg body weight
per day in nonobese patients and lower targets in obese patients
with cirrhosis in the absence of calorimetry measurements. The
recommended daily protein intake per these practice guidelines is
1.2–1.5 g/kg ideal body weight per day. In summary, the weight of
the evidence suggests that adequate sample size, stratiﬁcation by
frailty, and adequate calorie and protein intake are needed to
maximize the impact on outcomes.
Our review showed that most of the studies looked at the
feasibility of exercise interventions in this population while also
evaluating initial outcomes of physical rehabilitation on frailty
and sarcopenia metrics. These initial results are promising that
these interventions can be safe and feasible and can statistically
improve certain parameters of frailty and sarcopenia. Given the
negative consequences associated with frailty and sarcopenia and
the ﬁndings of our systematic review, we would strongly support
additional studies with larger sample sizes to evaluate primary
outcomes such as the survival beneﬁt of physical rehabilitation in
patients with advanced liver disease.
CONFLICTS OF INTEREST

Guarantor of the article: Ruben Hernaez, MD, MPH, PhD.
Speciﬁc author contributions: All authors participated in the stages
of the manuscript. Study concept and design: All authors. Acquisition
The American Journal of GASTROENTEROLOGY

Copyright © 2022 by The American College of Gastroenterology. Unauthorized reproduction of this article is prohibited.

1619

LIVER

Outcomes of Exercise Interventions in Patients

LIVER

1620

Jamali et al.

of data: T.R., T.J., G.B., A.S., and R.H. Analysis and interpretation of
data: T.R., T.J., R.H., P.T., and A.D. Drafting manuscript: T.R., T.J.,
and R.H. Critical revision of the manuscript for important
intellectual content: P.T., A.D., and R.H.. Study supervision: R.H..
Final approval of the version to be published: All authors. Agreement
to be accountable for all aspects of the work in ensuring that questions
related to the accuracy or integrity of any part of the article are
appropriately investigated and resolved: All authors.
Financial support: This work was supported by the Center for
Innovations in Quality, Eﬀectiveness and Safety (CIN 13-413),
Michael E. DeBakey VA Medical Center, Houston, TX. The
supporting body played no part in the literature search,
determination of study eligibility, interpretation of ﬁndings, or
preparation of the manuscript for publication. The views expressed in
this article are those of the authors and do not necessarily reﬂect the
position or policy of the Department of Veterans Aﬀairs or the
United States government.
Potential competing interests: None to report.

REFERENCES
1. Bunchorntavakul C, Reddy KR. Review article: Malnutrition/sarcopenia
and frailty in patients with cirrhosis. Aliment Pharmacol Ther 2020;51(1):
64–77.
2. Bojko M. Causes of sarcopenia in liver cirrhosis. Clin Liver Dis (Hoboken)
2019;14(5):167–70.
3. Ebadi M, Bhanji RA, Mazurak VC, et al. Sarcopenia in cirrhosis: From
pathogenesis to interventions. J Gastroenterol 2019;54(10):845–59.
4. Dasarathy S, Merli M. Sarcopenia from mechanism to diagnosis and
treatment in liver disease. J Hepatol 2016;65(6):1232–44.
5. Dhaliwal A, Armstrong MJ. Sarcopenia in cirrhosis: A practical overview.
Clin Med (Lond) 2020;20(5):489–92.
6. Nakaya Y, Okita K, Suzuki K, et al. BCAA-enriched snack improves
nutritional state of cirrhosis. Nutrition 2007;23(2):113–20.
7. Montano-Loza AJ, Angulo P, Meza-Junco J, et al. Sarcopenic obesity and
myosteatosis are associated with higher mortality in patients with
cirrhosis. J Cachexia Sarcopenia Muscle 2016;7(2):126–35.
8. Hara N, Iwasa M, Sugimoto R, et al. Sarcopenia and sarcopenic obesity are
prognostic factors for overall survival in patients with cirrhosis. Intern
Med 2016;55(8):863–70.
9. Feito Y, Magal M. ACSM’s Fitness Assessment Manual. Philadelphia:
Wolters Kluwer, 2021.
10. Liberati A, Altman DG, Tetzlaﬀ J, et al. The PRISMA statement for
reporting systematic reviews and meta-analyses of studies that evaluate
health care interventions: Explanation and elaboration. Ann Intern Med
2009;151(4):W65–94.
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